The Peptide Encyclopedia
Independent, sourced profiles of 30+ peptides. Each entry flags regulatory status honestly β approved medicine, research chemical, or somewhere in between β and links to primary research.
12 peptides
A synthetic 20-amino-acid direct thrombin inhibitor (hirudin analog), FDA-approved as an anticoagulant during percutaneous coronary intervention.
Carfilzomib (also known as Kyprolis) is a peptide catalogued under Therapeutic Peptides (Proteasome inhibitor (tetrapeptide)). It is described as: 20S proteasome. Documented context: Multiple myeloma. Neutral reference entry; EU status: EU-approved prescription medicine.
Ecallantide (also known as Kalbitor) is a peptide catalogued under Therapeutic Peptides (Plasma kallikrein inhibitor). It is described as: Plasma kallikrein. Documented context: Hereditary angioedema. Neutral reference entry; EU status: EU-approved prescription medicine.
A cyclic heptapeptide glycoprotein IIb/IIIa inhibitor (antiplatelet), FDA-approved for acute coronary syndrome and percutaneous coronary intervention.
Etelcalcetide (also known as Parsabiv) is a peptide catalogued under Therapeutic Peptides (Calcimimetic (D-amino acid heptapeptide)). It is described as: CaSR. Documented context: Secundaire hyperparathyroidism (CKD). Neutral reference entry; EU status: EU-approved prescription medicine.
Icatibant (also known as Firazyr) is a peptide catalogued under Therapeutic Peptides (Bradykinin B2 antagonist). It is described as: B2R antagonist. Documented context: Hereditary angioedema. Neutral reference entry; EU status: EU-approved prescription medicine.
Motixafortide (also known as Aphexda) is a peptide catalogued under Therapeutic Peptides (CXCR4 antagonist). It is described as: CXCR4. Documented context: Stem cell mobilization multiple myeloma. Neutral reference entry; EU status: EU-approved prescription medicine.
Recombinant human keratinocyte growth factor, FDA-approved to reduce severe oral mucositis in blood-cancer patients undergoing stem-cell transplant.
Pegcetacoplan (also known as Empaveli) is a peptide catalogued under Therapeutic Peptides (Compstatin analog (PEGylated)). It is described as: C3 complement. Documented context: PNH; GA. Neutral reference entry; EU status: EU-approved prescription medicine.
Trofinetide (also known as Daybue) is a peptide catalogued under Therapeutic Peptides (Glypromate analog (tripeptide)). It is described as: IGF-1 pathway modulator. Documented context: Rett syndrome. Neutral reference entry; EU status: EU-approved prescription medicine.
A synthetic cone-snail venom peptide (N-type calcium-channel blocker), FDA-approved for severe chronic pain via intrathecal infusion; carries a boxed warning.
Zilucoplan (also known as Zilbrysq) is a peptide catalogued under Therapeutic Peptides (Complement C5 inhibitor). It is described as: C5 complement. Documented context: Generalized myasthenia gravis. Neutral reference entry; EU status: EU-approved prescription medicine.